Radiofrequency ablation (RFA) can be a therapeutic option in medically inoperable lung cancer patients. In

 

Abstract

Radiofrequency ablation (RFA) can be a therapeutic 

option in medically inoperable lung cancer patients. In 

this study, we evaluated a prototype bipolar RFA device 

applicator that can be deployed from a standard 

endobronchial ultrasound (EBUS) bronchoscope to 

determine feasibility and histopathological analysis in 

animal models. Rabbit lung cancers were created by 

transbronchial injection of VX2 rabbit cancer cells. 

Once the tumors were developed, they were ablated 

transpleurally, under EBUS guidance using the prototype 

RFA device. The animals were then sacrificed for 

specimen resection. Pig inflammatory lung pseudo-tumors 

and lymphadenopathy were created by transbronchial 

injection of a talc paste and ablated transbronchially 

under EBUS guidance. Pigs were evaluated at five days, 

two weeks, and four weeks following ablation by 

bronchoscopy and cone-beam computed tomography before 

necropsy. Nicotinamide adenine dinucleotide hydrogen 

diaphorase staining was employed to measure the 

ablation area. Twenty-four VX2 rabbit tumors were 

ablated. The total ablated area ranged from 0.6 to 3.0 

cm2 (mean: 1.8 cm2), corresponding to a total energy 

range of 1 to 6 kJ. Six pig lung pseudo-tumors and five 

mediastinal lymph nodes (LNs) were ablated. Adjacent 

airway ulceration was observed in three ablations of 

LNs. These airway complications resolved within four 

weeks of RFA without any treatment. There was no 

hemoptysis, air embolism, respiratory distress, or 

other serious complication noted. In these two animal 

models, we provide evidence that EBUS-guided bipolar 

RFA is feasible and histopathology shows that can 

ablate lung tumors and mediastinal lymph nodes under 

real-time ultrasound guidance.

PMID: 32057971 [PubMed - as supplied by publisher]

14:59

Photo

Not included, change data exporting settings to 

download.

256×256, 6.0 KB

14:59

In reply to this message

pubmed: caandvteortroorpul

Management of cancer-related thrombosis in the era of 

direct oral anticoagulants: A comprehensive review of 

the 2019 ITAC-CME clinical practice guidelines. On 

behalf of the Groupe Francophone Thrombose et Cancer 

(GFTC).

Related Articles

Management of cancer-related thrombosis in the era of 

direct oral anticoagulants: A comprehensive review of 

the 2019 ITAC-CME clinical practice guidelines. On 

behalf of the Groupe Francophone Thrombose et Cancer 

(GFTC).

J Med Vasc. 2020 Feb;45(1):28-40

Authors: Rafii H, Frère C, Benzidia I, Crichi B, Andre 

T, Assenat E, Bournet B, Carpentier A, Connault J, 

Doucet L, Durant C, Emmerich J, Gris JC, Hij A, Le 

Hello C, Madelaine I, Messas E, Ndour A, Villiers S, 

Marjanovic Z, Ait Abdallah N, Yannoutsos A, Farge D